Bulk Manufacturer of Controlled Substances Application: Halo Pharmaceutical, Inc., 3979 [2015-01313]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 16 / Monday, January 26, 2015 / Notices
Drug Enforcement Administration
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[Docket No. DEA–392]
[FR Doc. 2015–01313 Filed 1–23–15; 8:45 am]
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
DEPARTMENT OF JUSTICE
SUPPLEMENTARY INFORMATION:
ACTION:
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to section 7 of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR
1301.33(a), this is notice that on May 29,
2014, Euticals, Inc., 2460 W. Bennett
Street, Springfield, Missouri 65807–
1229, applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Controlled substance
Schedule
emcdonald on DSK67QTVN1PROD with NOTICES
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Oripavine (9330) ...........................
Tapentadol (9780) ........................
I
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
In reference to Amphetamine (1100),
the company plans to acquire the listed
controlled substance in bulk from a
domestic source in order to manufacture
other controlled substances in bulk for
distribution to its customers.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–01312 Filed 1–23–15; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
18:48 Jan 23, 2015
Jkt 235001
3979
BILLING CODE P
Bulk Manufacturer of Controlled
Substances Application: Halo
Pharmaceutical, Inc.
Notice of application.
Drug Enforcement Administration
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before March 27, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers, of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to section 7 of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR
1301.33(a), this is notice that on July 21,
2014, Halo Pharmaceutical, Inc., 30
North Jefferson Road, Whippany, New
Jersey 07981, applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
DATES:
Controlled substance
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Schedule
I
II
The company plans to manufacture
Hydromorphone HCl for sale to other
manufacturers and to manufacture other
controlled substances for distribution to
its customers. Dihydromorphine is an
intermediate in the manufacture of
Hydromorphone and is not for
commercial distribution.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before February 25, 2015. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
February 25, 2015.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of importers,
of controlled substances (other than
final orders in connection with
suspension, denial, or revocation of
registration) has been redelegated to the
Deputy Assistant Administrator of the
DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to section 7 of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on June
16, 2014, Fisher Clinical Services, Inc.
7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 80, Number 16 (Monday, January 26, 2015)]
[Notices]
[Page 3979]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01313]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Halo
Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before March 27, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, and dispensers, of controlled substances (other than
final orders in connection with suspension, denial, or revocation of
registration) has been redelegated to the Deputy Assistant
Administrator of the DEA Office of Diversion Control (``Deputy
Assistant Administrator'') pursuant to section 7 of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR 1301.33(a), this is notice that on July
21, 2014, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany,
New Jersey 07981, applied to be registered as a bulk manufacturer of
the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to manufacture Hydromorphone HCl for sale to
other manufacturers and to manufacture other controlled substances for
distribution to its customers. Dihydromorphine is an intermediate in
the manufacture of Hydromorphone and is not for commercial
distribution.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01313 Filed 1-23-15; 8:45 am]
BILLING CODE P
